CMAX - Study on Nasal Spray/ antiviralCMAX Clinical Research centre on North Terrace, Adelaide, increased its inpatient beds to 55 in 2020. CMAX Clinical Research centre, one of Australia’s largest and most experienced, on North Terrace, Adelaide, saw an unprecedented demand for medical clinical trials during the 2020 Covid pandemic. Established in 1993, CMAX specialised in early-phase and first-time-in-human trials and initiated about 50 trials in 2020. This added to the 600 trials, including more than 100 first-time-in-human studies, for national and international clints from pharmaceutical, biotechnology and medical device companies. Three trials in 2002 looked at treatment options for Covid-19, including a nasal spray and a novel antiviral treatment. CMAX employed 200 staff in 2020 at its new purpose-built centre on North Terrace opposite the Royal Adelaide Hospital (where it was originally located) and Adelaide BioMed City, one of the largest health and life sciences clusters in the southern hemisphere. CMAX, as Adelaide BioMed City's clinical trials unit, was contributing to creating the next generation of medical technologies and medicines. CMAX staff numbers had almost doubled in the previous three years and it was looking to expand in 2021 with inpatient beds up to 55. Attracting more volunteers to take part in the growing clinical trial space was also a priority. Also in 2020, CMAX launched Fusion clinical research allowing health professionals to provide clinical trials in general practitioners’ (GPs) clinics. A dedicated team from CMAX would connect pharmaceutical, biotech, digital health and clinical research organisations to GPs and their patients who were keen to take part in clinical trial research within a GP clinic. This was expected to transform clinical medical trials to be done in new community settings. From 2002, CMAX became part of IDT Australia Limited that had partnered with the I'rom Group since 2012. In 2016, the I'rom Group bought CMAX shares and welcomed it into that group.